Virginia Retirement Systems ET AL reduced its position in Meridian Bioscience Inc. (NASDAQ:VIVO) by 18.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 62,700 shares of the company’s stock after selling 14,300 shares during the period. Virginia Retirement Systems ET AL owned 0.15% of Meridian Bioscience worth $897,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VIVO. Advisor Group Inc. grew its stake in shares of Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock worth $122,000 after purchasing an additional 1,537 shares during the period. State of Alaska Department of Revenue grew its stake in shares of Meridian Bioscience by 77.5% during the second quarter. State of Alaska Department of Revenue now owns 8,273 shares of the company’s stock worth $130,000 after purchasing an additional 3,613 shares during the period. Municipal Employees Retirement System of Michigan grew its stake in shares of Meridian Bioscience by 3.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock worth $157,000 after purchasing an additional 370 shares during the period. Petrus Trust Company LTA acquired a new stake in shares of Meridian Bioscience during the second quarter worth $178,000. Finally, Eqis Capital Management Inc. acquired a new stake in shares of Meridian Bioscience during the third quarter worth $184,000. 87.03% of the stock is owned by institutional investors.
Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) opened at $14.10 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 4.04 and a current ratio of 5.85. Meridian Bioscience Inc. has a 52 week low of $10.75 and a 52 week high of $18.58. The company has a market capitalization of $616.36, a price-to-earnings ratio of 21.47 and a beta of 0.89.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, November 9th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. Meridian Bioscience had a return on equity of 17.03% and a net margin of 10.74%. The business had revenue of $49.70 million during the quarter, compared to analysts’ expectations of $48.28 million. During the same period in the previous year, the firm earned $0.14 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. analysts anticipate that Meridian Bioscience Inc. will post 0.66 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Monday, November 20th were paid a $0.125 dividend. The ex-dividend date of this dividend was Friday, November 17th. This represents a $0.50 dividend on an annualized basis and a yield of 3.55%. Meridian Bioscience’s payout ratio is 98.04%.
A number of equities research analysts recently commented on VIVO shares. Canaccord Genuity reaffirmed a “hold” rating and set a $14.00 price objective on shares of Meridian Bioscience in a research note on Friday, October 13th. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th. Two analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. Meridian Bioscience has an average rating of “Hold” and a consensus price target of $11.50.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://ledgergazette.com/2017/12/09/virginia-retirement-systems-et-al-lowers-stake-in-meridian-bioscience-inc-vivo.html.
Meridian Bioscience Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.